Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027

Q32 Bio Inc.

Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.
Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.
Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.
Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Q32 Bio Inc. reported financial results for quarter ended December 31, 2025.

Period: quarter ended December 31, 2025
Result: reported results

Exact text from the filing

Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended December 31, 2025, and provided recent corporate updates.

View on SEC.gov

Browse all earnings releases →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-099328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.